Company faces potential delisting following compliance notice from NYSE American
- Azitra received a notice of non-compliance from NYSE American.
- The company must act to avoid potential delisting.
- Shareholders are informed of the situation.
Azitra, a biotechnology company, has received a notice from NYSE American citing non-compliance with its listing standards. This notice signals that the company may be at risk of being delisted unless corrective actions are taken. The non-compliance was prompted due to the company's failure to meet certain quantitative listing standards as set by the exchange.
In response to the notice, Azitra is required to submit a plan outlining how it intends to regain compliance with the NYSE American's requirements. The company is actively reviewing its options and possible strategies to address this issue effectively. The public announcement regarding this situation aims to keep shareholders appropriately informed about the status of the company's listing.
Azitra's management acknowledges the importance of adhering to exchange requirements and is committed to taking the necessary steps to improve its compliance. The company’s future on the exchange will depend on its ability to fulfill the corrective measures outlined by NYSE American.
